Benoît J. Van Den Eynde
Director
Ludwig Center at Brussels
Ludwig Institute for Cancer Research
United States of America
Biography
I am an expert in tumor immunology (MD, PhD) and I am currently Director of the Brussels Branch of the Ludwig Institute for Cancer Research and co-director of the de Duve Institute. I am also Full Professor of Immunology at the Université catholique de Louvain in Brussels and I train young scientists, including PhD students, medical students and postdoctoral Fellows form all over the world. I serve as member of several national and international scientific committees and editorial boards, and I am a full member of the Belgian Royal Academy of Medicine. I am also co-founder of iTeos Therapeutics, a biotechnology company based in Gosselies (Belgium) launched in 2012 as a spin-off of Ludwig Cancer Research. Its activity consists in developing small molecule immunomodulators for cancer treatment. Its first compound, an IDO inhibitor, will soon enter clinical testing in cancer patients.
Research Interest
Tumor immunology, cancer treatment, molecule immunomodulators
Publications
-
Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch M-P, Theate I, Parmentier N and Van den Eynde BJ. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. ​Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18599-604. ​Epub 2010 Oct 11.​
-
Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K-i, Yang JC, Rosenberg SA, Van den Eynde BJ. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):E323-31. Epub 2011 Jun 13.
-
Huijbers IJ, Soudja SM, Uyttenhove C, Buferne M, Inderberg-Suso EM, Colau D, Pilotte L, Powis de Tenbossche CG, Chomez P, Brasseur F, Schmitt-Verhulst AM, Van den Eynde BJ. Minimal tolerance to a tumor antigen encoded by a cancer-germline gene. J Immunol. 2012 Jan 1;188(1):111-21. Epub 2011 Dec 2.
